Skip to content
DataLookout
Menu

NCT07943273

Treatment Outcomes and Molecular Prognostic Factors in TP53 Mutated Myeloid Neoplasms

StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Description of clinical outcomes according to treatment patterns
Timeframe: Time from first administration of induction chemotherapy to death from any cause, assessed up to 01/01/2027

Secondary (3)

HCT as a time-dependent exposure.
Pre-HCT TP53 variant allelic frequency (VAF)
Molecular prognostic

Arms and interventions

TP53 mutated myeloid neoplasms from Nice University Hospital

We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure

TP53 mutated myeloid neoplasms from Saint-Louis University Hospital

We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure

Other: Treatment outcomes and molecular prognostic

Sites

1 site in 1 country

  • CHU de NiceNice, Alpes Maritimes, France